Drug Trial Radar · NCT03121638
Safety Study of NBP608 in Healthy Adult Volunteers
Last checked: Nov 19, 2026Latest source record: Apr 20, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
150
Actual
Start
Nov 2012
Primary completion
Feb 2013
Study completion Mar 2013
Sponsor
- Lead sponsor
- SK Chemicals Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Apr 20, 2017
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 20 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
* Indication: Protection against varicella and herpes zoster * Study Objectives * Primary: Safety and tolerability assessment after single dose administration of NBP608 * Secondary: immunogenicity assessment after single dose administration of NBP608
Conditions
- Varicella Zoster
- Immunization; Infection
Interventions
VARIVAXBiological
Preparation of Oka/Merck strain of live, attenuated varicella zoster virus
ZOSTAVAXBiological
Preparation of Oka/Merck strain of live, attenuated varicella zoster virus
NBP6081Biological
Preparation of Oka/SK strain of live, attenuated varicella zoster virus
NBP6082Biological
Preparation of Oka/SK strain of live, attenuated varicella zoster virus
NBP6083Biological
Preparation of Oka/SK strain of live, attenuated varicella zoster virus
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence Rate of Adverse EventTime frame: 42days after Investigation Product Vaccination
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Korea University Guro Hospital
Seoul, South Korea
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.